Teva Has Nasal Naloxone Nod For First US Narcan Rival

25 Apr 2019

Teva has received FDA approval for the first US generic naloxone nasal spray after a 30-month stay linked to ongoing patent litigation expired. Launch plans have not yet been revealed. Meanwhile, the Israeli firm has also introduced the first generic version of VESIcare in the US.

Teva Has Approval For A Generic Version Of Narcan Nasal Spray • Source: Shutterstock

Teva Has Nasal Naloxone Nod For First US Narcan Rival

More from Regulation

More from Policy & Regulation